APRI vs. CYCN, BNOX, OBSV, CMMB, TENX, ADXN, ASLN, HEPA, NCNA, and EFTR
Should you be buying Apricus Biosciences stock or one of its competitors? The main competitors of Apricus Biosciences include Cyclerion Therapeutics (CYCN), Bionomics (BNOX), ObsEva (OBSV), Chemomab Therapeutics (CMMB), Tenax Therapeutics (TENX), Addex Therapeutics (ADXN), ASLAN Pharmaceuticals (ASLN), Hepion Pharmaceuticals (HEPA), NuCana (NCNA), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "medical" sector.
Cyclerion Therapeutics (NASDAQ:CYCN) and Apricus Biosciences (NASDAQ:APRI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, community ranking, media sentiment, risk and dividends.
Apricus Biosciences' return on equity of -111.79% beat Cyclerion Therapeutics' return on equity.
Cyclerion Therapeutics has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500. Comparatively, Apricus Biosciences has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500.
75.6% of Cyclerion Therapeutics shares are owned by institutional investors. Comparatively, 19.9% of Apricus Biosciences shares are owned by institutional investors. 13.1% of Cyclerion Therapeutics shares are owned by company insiders. Comparatively, 2.3% of Apricus Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Apricus Biosciences has higher revenue and earnings than Cyclerion Therapeutics. Cyclerion Therapeutics is trading at a lower price-to-earnings ratio than Apricus Biosciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cyclerion Therapeutics had 1 more articles in the media than Apricus Biosciences. MarketBeat recorded 1 mentions for Cyclerion Therapeutics and 0 mentions for Apricus Biosciences. Apricus Biosciences' average media sentiment score of 0.00 equaled Cyclerion Therapeutics'average media sentiment score.
Apricus Biosciences received 196 more outperform votes than Cyclerion Therapeutics when rated by MarketBeat users. Likewise, 69.91% of users gave Apricus Biosciences an outperform vote while only 58.62% of users gave Cyclerion Therapeutics an outperform vote.
Summary
Cyclerion Therapeutics beats Apricus Biosciences on 7 of the 13 factors compared between the two stocks.
Get Apricus Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for APRI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Apricus Biosciences Competitors List
Related Companies and Tools
